The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Open accessAbstract
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. Pralsetinib is a highly potent, selective RET inhibitor. Methods: ARROW, a phase 1/2, open-label study conducted in 13 countries across 84 sites, enrolled patients with RET-altered locally advanced/metastatic solid tumours, including RET-mutant medullary thyroid and RET fusion–positive thyroid cancers. Phase 2 primary endpoints, assessed for patients who received 400 mg once-daily oral pralsetinib, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1·1; blinded independent central review) and safety. Tumour response was assessed for patients with RET-mutant medullary thyroid cancer who had received prior cabozantinib and/or vandetanib or were ineligible for standard therapy and patients with previously treated RET fusion–positive thyroid cancer; safety was assessed for all patients with RET-altered thyroid cancer. Findings: Between Mar 17, 2017, and May 22, 2020, 122 patients with RET-mutant medullary and 20 with RET fusion–positive thyroid cancers were enrolled. Among patients with baseline measurable disease who received pralsetinib by July 11, 2019 (enrolment cut-off), response rates were 71% (95% confidence interval [CI] 48–89; n=15/21) in patients with treatment-naïve RET-mutant medullary thyroid cancer and 60% (95% CI 46–73; n=33/55) in patients who previously received cabozantinib and/or vandetanib, and 89% (95% CI 52–100; n=8/9) in patients with RET fusion–positive thyroid cancer (all confirmed for each group). Common (≥10%) grade ≥3 treatment-related adverse events among patients with RET-altered thyroid cancer enrolled by May 22, 2020 (n=142) were hypertension (17%), neutropenia (13%), lymphopenia (12%), and anaemia (10%); 4% discontinued due to treatment-related events. Interpretation: Pralsetinib is a new, well-tolerated, potent once-daily oral treatment option for patients with RET-altered thyroid cancer. Funding: Blueprint Medicines Corporation, Cambridge, Massachusetts, USA
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationWells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Self-citationEfficacy of Selpercatinib in RET -Altered Thyroid Cancers
Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 790
Self-citationRoman, S., Lin, R., & Sosa, J. A. (2006) · Cancer · doi:10.1002/cncr.22244 · Cited by 548
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00247-3 · Cited by 440
Self-citation
Cited by
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationRingel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Self-citationBoucai, L., Zafereo, M., & Cabanillas, M. E. (2024) · JAMA · doi:10.1001/jama.2023.26348 · Cited by 701
Chen, D. W., Lang, B. H. H., McLeod, D. S. A., Newbold, K., & Haymart, M. R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00020-x · Cited by 590
The next generation of evidence-based medicine
Subbiah, V. (2023) · Nature Medicine · doi:10.1038/s41591-022-02160-z · Cited by 544
Self-citation
Metadata
- Authors
- Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C.-C., Godbert, Y., Sarker, D., Miller, S. G., Clifford, C., Zhang, H., Turner, C. D., & Taylor, M. H.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 9
- Issue
- 8
- Pages
- 491-501
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3166643980
- Cited by
- 366
- References
- 23
- FWCI
- 39.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00120-0
- The paper
- Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C.-C., Godbert, Y., . . . Taylor, M. H. (2021). Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00120-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.